Ebsteins anomaly of the tricuspid valve surgery

Ebsteins anomaly of the tricuspid valve Microchapters
Home
Patient Information
Overview
Historical Perpective
Classification
Pathophysiology
Causes
Differentiating Ebstein's Anomaly from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
Echocardiography
CT
MRI
Other Imaging Findings
Other diagnostic studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Case Studies
Case #1
Ebsteins anomaly of the tricuspid valve surgery On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Ebsteins anomaly of the tricuspid valve surgery All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Ebsteins anomaly of the tricuspid valve surgery
CDC on Ebsteins anomaly of the tricuspid valve surgery
Ebsteins anomaly of the tricuspid valve surgery in the news
Blogs on Ebsteins anomaly of the tricuspid valve surgery
Directions to Hospitals Treating Type page name here
Risk calculators and risk factors for Ebsteins anomaly of the tricuspid valve surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] and Claudia P. Hochberg, M.D. [2]

Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [3]

Surgery

- Tricuspid valve repair or replacement (when possible repair is preferable to replacement as it is associated with a lower mortality rate and fewer complications).

• Atrial septal defect repair.
• Right atrial plication (unclear whther this improves right ventricular function).
• Cardiac defibrillator implantation.
• Accessory pathways may require surgical intervention or ablation.

Hospital mortality at the Mayo for valve reconstruction is 6.7%. Only 1.6% in the Mayo series required reoperation. Long term follow up in the Mayo series showed 92% to have Class I or II symptoms and a 10 year mortality rate of 8%.

Generally, surgical treatment improves the exercise intolerance from NYHA-FC III or IV to NYHA-FC I or II.

Regardless of severity of the Ebstein’s Anomaly and type of treatment, risk of sudden death remains an important issue in patients with Ebstein's anomaly.